You can edit almost every page by Creating an account. Otherwise, see the FAQ.

Hendrik Jan Leonard Ankersmit

From EverybodyWiki Bios & Wiki

Hendrik Jan Leonard Ankersmit (* 1970 in Durban) is a thoracic surgeon, translational researcher and entrepreneur.


Hendrik Jan L. Ankersmit was born in Durban, South Africa, and grew up in Johannesburg, South Africa, and Klagenfurt, Austria. He studied medicine and philosophy, earning his doctorate in 1994. He then performed postdoctoral research at Columbia University (1997–1998, College of Physicians and Surgeons, NY), and underwent specialized training in general and thoracic surgery. In 2004, he completed his habilitation, with work pertaining to immunological alterations after implantation of artificial hearts (ventricular assist devices). In 1999, he founded the “Applied Immunology” working group at the Medical University of Vienna. Ankersmit is working as consultant at the Thoracic Surgery Department at the Medical Unviersity of Vienna.

Scientific Work[edit]

Ankersmit’s notable scientific contributions include providing the first descriptions of leucocyte apoptosis and programmed cell death in vivo in patients supported by ventricular assist devices (VADs), in patients with sepsis, in patients undergoing dialysis treatment, and in heart transplant patients diagnosed with transplant-associated vasculopathy (1999–2003).[1][2][3][4][5].

He was the first to describe an alpha-Gal-specific humoral immune response in recipients of biological prostheses (2005–2009) [6][7]and provided the first description of CD32-mediated platelet aggregation induced by IVIG and ATG in vitro (2003, 2008) [8][9]

He was the first to identify alveolar pneumo-epithelial cells as the main producers of soluble ST2 (2010) [10], and the first to describe the post-CABG immune status as immunological anergy (2005–2014) [11][12][13][14][15].

Ankersmit first identified an autoimmune state in patients diagnosed with chronic obstructive pulmonary disease (COPD) (2009–2013)[16][17], and performed serum biomarker research in patients with COPD and lung carcinoma (2009–2012) [18][19][20] as well as the first prospective study to investigate air trapping/emphysema in heavy smokers with normal lung function by means of multi-slice computer tomography (2015)[21]

In contrast to all prior stem cell literature, Ankersmit demonstrated for the first time that apoptotic white blood cells (peripheral blood mononuclear cells; PBMCs) and their secretory product prevented experimental myocardial infarction (2009). This investigation raised the first questions regarding the necessity of using stem cells or their secretory product in regenerative medicine. Based on these datasets, APOSECTM was patented in 2008. Over the following years, it was demonstrated that this PBMC-derived “cell-free biological” substance prevented inflammatory damage in multiple indications, including acute myocardial infarction, myocarditis, stroke, spinal cord injury, and wounding (2011–2018). In 2017, the stressed white blood secretome (GMP APOSECTM) was tested for the first time in a PHASE I human trial.

This article "Hendrik Jan Leonard Ankersmit" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Hendrik Jan Leonard Ankersmit. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

  1. J Thorac Cardiovasc Surg. 2002 Mar;123(3):557-61. doi: 10.1067/mtc.2002.120011.
  2. Lancet. 1999 Aug 14;354(9178):550-5.doi: 10.1016/S0140-6736(98)10359-8.
  3. Biochem Biophys Res Commun. 2003 Sep 5;308(4):840-6. doi: 10.1016/S0006-291X(03)01482-7.
  4. Biochem Biophys Res Commun. 2003 Aug 29;308(3):581-5. doi: 10.1016/S0006-291X(03)01389-5.
  5. Clin Exp Immunol. 2002 Jan;127(1):183-9. doi: 10.1046/j.1365-2249.2002.01741.x.
  6. Eur J Clin Invest. 2005 Jan;35(1):17-23. doi: 10.1111/j.1365-2362.2005.01441.x.
  7. Thorac Cardiovasc Surg. 2009 Jun;57(4):191-5. doi: 10.1055/s-0029-1185395.
  8. Am J Transplant. 2003 Jun;3(6):754-9.doi: 10.1034/j.1600-6143.2003.00150.x.
  9. Br J Dermatol. 2008 Sep;159(3):578-84. doi: 10.1111/j.1365-2133.2008.08700.x.
  10. Cardiovasc Res. 2010 Sep 1;87(4):769-77. doi: 10.1093/cvr/cvq104.
  11. Clin Lab. 2005;51(11-12):657-63.
  12. Clin Lab. 2006;52(5-6):255-61.
  13. Ann Thorac Surg. 2008 Jan;85(1):80-7. doi: 10.1016/j.athoracsur.2007.06.049.
  14. Eur J Cardiothorac Surg. 2013 Aug;44(2):282-7. doi: 10.1093/ejcts/ezs659.
  15. J Cardiovasc Surg (Torino). 2014 Dec;55(6):849-56.
  16. Clin Exp Immunol. 2009 Mar;155(3):466-75. doi: 10.1111/j.1365-2249.2008.03835.x.
  17. Wien Klin Wochenschr. 2013 Mar;125(5-6):150-5. doi: 10.1007/s00508-013-0340-4.
  18. Clin Lab. 2009;55(1-2):31-40.
  19. J Clin Lab Anal. 2009;23(6):372-9. doi: 10.1002/jcla.20348.
  20. Clin Chim Acta. 2012 Jul 11;413(13-14):1115-20. doi: 10.1016/j.cca.2012.03.008.
  21. Clin Respir J. 2015 Jul;9(3):375-9. doi: 10.1111/crj.12139.